A number of other equities research analysts have also recently weighed in on the stock. Leerink Swann started coverage on shares of Aclaris Therapeutics in a research report on Tuesday, November 29th. They issued an outperform rating for the company. Zacks Investment Research upgraded shares of Aclaris Therapeutics from a hold rating to a buy rating and set a $35.00 price objective on the stock in a research note on Wednesday, March 1st. Finally, Guggenheim lifted their price objective on shares of Aclaris Therapeutics from $35.00 to $40.00 and gave the company a buy rating in a research note on Wednesday, March 15th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the stock. The stock presently has an average rating of Buy and a consensus target price of $36.25.
Aclaris Therapeutics (NASDAQ:ACRS) opened at 28.88 on Thursday. Aclaris Therapeutics has a 52-week low of $14.12 and a 52-week high of $33.25. The company has a 50 day moving average price of $28.79 and a 200 day moving average price of $26.33. The firm’s market capitalization is $618.96 million.
Aclaris Therapeutics (NASDAQ:ACRS) last posted its quarterly earnings results on Wednesday, March 15th. The company reported ($0.49) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.59) by $0.10. On average, equities analysts forecast that Aclaris Therapeutics will post ($3.11) EPS for the current fiscal year.
var userip;Your IP Address: document.write(userip);
In other Aclaris Therapeutics news, Director Anand Mehra sold 750,000 shares of Aclaris Therapeutics stock in a transaction on Tuesday, January 10th. The shares were sold at an average price of $28.25, for a total value of $21,187,500.00. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, major shareholder Ventures Fund Vii L.P. Vivo sold 425,000 shares of Aclaris Therapeutics stock in a transaction on Thursday, March 2nd. The shares were sold at an average price of $30.82, for a total transaction of $13,098,500.00. The disclosure for this sale can be found here. Insiders own 46.40% of the company’s stock.
A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Dynamic Technology Lab Private Ltd acquired a new position in Aclaris Therapeutics during the fourth quarter worth approximately $209,000. Strs Ohio raised its position in shares of Aclaris Therapeutics by 170.0% in the third quarter. Strs Ohio now owns 8,100 shares of the company’s stock worth $207,000 after buying an additional 5,100 shares during the period. Citadel Advisors LLC purchased a new position in shares of Aclaris Therapeutics during the third quarter worth about $238,000. Boothbay Fund Management LLC purchased a new position in shares of Aclaris Therapeutics during the fourth quarter worth about $264,000. Finally, A.R.T. Advisors LLC purchased a new position in shares of Aclaris Therapeutics during the fourth quarter worth about $325,000. Institutional investors own 61.94% of the company’s stock.
About Aclaris Therapeutics
Aclaris Therapeutics, Inc is a United States-based clinical-stage specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing drugs to address the needs in dermatology. Its lead drug candidate, A-101 Topical Solution, is a hydrogen peroxide topical solution that the Company is developing as a prescription treatment for seborrheic keratosis (SK).
Receive News & Ratings for Aclaris Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.